Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Rallybio Corp | Chief Medical Officer | Option (Right to Buy) | 120K | $212K | $1.77 | Feb 15, 2024 | Direct |
MBX Biosciences, Inc. | Director | Stock Option (Right to Buy) | 16K | Sep 12, 2024 | Direct | ||
REATA PHARMACEUTICALS INC | Director | Class A common stock | 0 | $172.03 | Sep 26, 2023 | Direct | |
REATA PHARMACEUTICALS INC | Director | Stock Option (right to buy) | 0 | Sep 26, 2023 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
MBX | MBX Biosciences, Inc. | Sep 12, 2024 | 1 | $0 | 4 | Sep 13, 2024 | Director |
MBX | MBX Biosciences, Inc. | Sep 12, 2024 | 0 | $0 | 3 | Sep 12, 2024 | Director |
RLYB | Rallybio Corp | Feb 15, 2024 | 1 | $0 | 4 | Feb 16, 2024 | Chief Medical Officer |
RETA | REATA PHARMACEUTICALS INC | Sep 26, 2023 | 6 | $0 | 4 | Sep 26, 2023 | Director |
RETA | REATA PHARMACEUTICALS INC | Jun 7, 2023 | 4 | $222K | 4 | Jun 9, 2023 | Director |
RLYB | Rallybio Corp | Feb 6, 2023 | 1 | $0 | 4 | Feb 6, 2023 | Chief Medical Officer |
RETA | REATA PHARMACEUTICALS INC | Jul 11, 2022 | 6 | $317K | 4 | Jul 12, 2022 | Director |
RETA | REATA PHARMACEUTICALS INC | Jul 11, 2022 | 0 | $0 | 3 | Jul 11, 2022 | Director |
RLYB | Rallybio Corp | Feb 7, 2022 | 1 | $0 | 4 | Feb 9, 2022 | Chief Medical Officer |
RLYB | Rallybio Corp | Jul 29, 2021 | 0 | $0 | 3 | Jul 29, 2021 | Chief Medical Officer |